← European Medicine Shortage Tracker · all medicines
Levothyroxin-Natrium (Ph.Eur.) currently has availability issues reported in 1 European register: Germany.
Shortage ATC H03AA01 · also listed as: Levothyroxin-Natrium (Ph.Eur.) · data refreshed 7 August 2026
As of 7 August 2026, 1 of the 10 tracked registers list current availability issues for Levothyroxin-Natrium (Ph.Eur.), covering 2 affected product presentations. The longest-running open report was filed in Germany on 2024-11-01 and has now been open for about 21 months. Where agencies state a cause, manufacturing problems lead with 2 of the 2 stated-cause reports. The furthest expected-resolution date currently on file is 2026-12-31; the earliest is 2026-12-31. Registers in Germany indicate that alternatives or equivalents are available — a pharmacist or doctor can advise on switching. In the WHO ATC classification, Levothyroxin-Natrium (Ph.Eur.) is coded H03AA01 — a medicine acting on systemic hormonal preparations — so clinically related products appear under “Related medicines” below.
| Where | Status & products | Since | Expected end | Reason / alternatives | Source |
|---|---|---|---|---|---|
| 🇩🇪 Germany | Shortage Thevier 100 + 1 more productsThevier 50 | 2024-11-01 | 2026-12-31 | Unzureichende Produktionskapazitäten Alternatives: Levothyroxin Abdi 100 Mikrogramm Tabletten - Einreichungsnummer: 7001601 | register ↗ |
Every individual register entry for Levothyroxin-Natrium (Ph.Eur.) in the tracked sources, newest first — including resolved and discontinued reports.
| Reg. | Product | Status | Reported | Expected end | Stated reason |
|---|---|---|---|---|---|
| 🇩🇪 DE | Thevier 50 | Shortage | 2024-12-01 | 2026-12-31 | Unzureichende Produktionskapazitäten |
| 🇩🇪 DE | Thevier 100 | Shortage | 2024-11-01 | 2026-12-31 | Unzureichende Produktionskapazitäten |
Yes. As of 7 August 2026, availability issues are reported in: Germany. Availability is national — a shortage in one country does not mean it is short everywhere.
Agency prognoses on file range from 2026-12-31 to 2026-12-31. These are manufacturer-reported estimates and frequently move; check the linked register entry for the latest date.
2 of the active register entries indicate alternatives or equivalents (same active substance or an alternative treatment). Do not switch on your own — a pharmacist or prescriber can confirm the right substitute in your country.
Directly from the official medicines-agency register that lists Levothyroxin-Natrium (Ph.Eur.): BfArM (Germany). Every row on this page links to the underlying official record, and the dataset is refreshed from the primary sources every morning. Cross-language matching groups the same active substance across registers, so national spellings all resolve to this page.
Pharmacies, patient sites and newsrooms are welcome to embed the live status of Levothyroxin-Natrium (Ph.Eur.) — free, with attribution. Copy this snippet:
<iframe src="https://www.mobidoctor.eu/medicine-shortages/medicine-shortages/levothyroxin-natrium-ph-eur/embed.html" width="100%" height="150" loading="lazy" style="border:1px solid #e1e0d9;border-radius:12px" title="Levothyroxin-Natrium (Ph.Eur.) availability in Europe"></iframe> <p style="font-size:12px">Source: <a href="https://www.mobidoctor.eu/medicine-shortages/medicine-shortages/levothyroxin-natrium-ph-eur/">Levothyroxin-Natrium (Ph.Eur.) shortage status — European Medicine Shortage Tracker</a> by MobiDoctor</p>